Drug Trial Radar · NCT06737731
A Phase I/II Clinical Study of SHR-1681 for Injection in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Jan 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
300
Planned (sponsor's estimate)
Start
Jan 21, 2025
Primary completion
Nov 2026
Study completion Jul 2027
Sponsor
- Lead sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 17, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is an open-label, multicenter Phase I/II clinical trial to evaluate the safety, tolerability, pharmacokinetics and efficacy of SHR-1681 for injection in patients with advanced solid tumors.
Conditions
- Malignant Solid Tumors
Interventions
SHR-1681Drug
SHR-1681 for Injection will be administrated per dose level in which the patients are assigned.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum tolerated dose (MTD)Time frame: 12 months.
- Maximum administered dose (MAD)Time frame: 12 months.
- Recommended Phase 2 dose (RP2D)Time frame: 12 months.
- Incidence and severity of adverse events (AEs)Time frame: Approximately 3 years.
- Incidence and severity of serious adverse events (SAEs)Time frame: Approximately 3 years.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Dongfang Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.